Nexgen to join WHO's R&D project for rabies antibody
Published: 2006-01-16 06:58:00
Updated: 2006-01-16 06:58:00
Nexgen, a plant genetic engineering venture company, announced on Jan. 10 about their participation in the WHO's project for the rabies antibody development by the use of plant as a part of "Pharma-Planta consortium" proceeded by EU.
The company said "Our molecular farming technology has been...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.